- Home
- IMRN vs MEIP Comparison
IMRN vs MEIP Comparison
Compare IMRN & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- MEIP
- Stock Information
- Founded
- IMRN 1994
- MEIP 2000
- Country
- IMRN Australia
- MEIP United States
- Employees
- IMRN N/A
- MEIP N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- MEIP Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- MEIP Health Care
- Exchange
- IMRN Nasdaq
- MEIP Nasdaq
- Market Cap
- IMRN 15.0M
- MEIP 16.3M
- IPO Year
- IMRN N/A
- MEIP 2003
- Fundamental
- Price
- IMRN $2.15
- MEIP $2.87
- Analyst Decision
- IMRN Strong Buy
- MEIP Hold
- Analyst Count
- IMRN 1
- MEIP 2
- Target Price
- IMRN $5.00
- MEIP $7.00
- AVG Volume (30 Days)
- IMRN 21.6K
- MEIP 36.2K
- Earning Date
- IMRN 02-26-2025
- MEIP 02-11-2025
- Dividend Yield
- IMRN N/A
- MEIP N/A
- EPS Growth
- IMRN N/A
- MEIP N/A
- EPS
- IMRN N/A
- MEIP N/A
- Revenue
- IMRN $3,271,194.00
- MEIP N/A
- Revenue This Year
- IMRN N/A
- MEIP N/A
- Revenue Next Year
- IMRN N/A
- MEIP $300.00
- P/E Ratio
- IMRN N/A
- MEIP N/A
- Revenue Growth
- IMRN 171.67
- MEIP 33.76
- 52 Week Low
- IMRN $1.59
- MEIP $2.30
- 52 Week High
- IMRN $5.96
- MEIP $4.97
- Technical
- Relative Strength Index (RSI)
- IMRN 56.18
- MEIP 66.22
- Support Level
- IMRN $1.85
- MEIP $2.56
- Resistance Level
- IMRN $2.20
- MEIP $2.78
- Average True Range (ATR)
- IMRN 0.22
- MEIP 0.15
- MACD
- IMRN 0.01
- MEIP 0.04
- Stochastic Oscillator
- IMRN 57.47
- MEIP 100.00
About IMRN Immuron Limited
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.